Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Adalimumab (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMBAAT
- 02 Mar 2022 Planned End Date changed from 1 Jan 2022 to 1 Sep 2022.
- 02 Mar 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Sep 2022.
- 02 Mar 2022 Planned initiation date changed from 1 May 2021 to 1 Sep 2021.